These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 33408716)

  • 41. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective.
    Lan H; Zhang W; Jin K; Liu Y; Wang Z
    Drug Deliv; 2020 Dec; 27(1):1248-1262. PubMed ID: 32865029
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stimuli-Sheddable Nanomedicine Overcoming Pathophysiological Barriers for Potentiating Immunotherapy of Cancer.
    Wang J; Zhou M; Chen F; Liu X; Gao J; Wang W; Wang H; Yu H
    J Biomed Nanotechnol; 2021 Aug; 17(8):1486-1509. PubMed ID: 34544528
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.
    Sanmamed MF; Chen L
    Cell; 2018 Oct; 175(2):313-326. PubMed ID: 30290139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nanoparticles: Properties and Applications in Cancer Immunotherapy.
    Iscaro A; Howard NF; Muthana M
    Curr Pharm Des; 2019; 25(17):1962-1979. PubMed ID: 31566122
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gold Nanoparticles in Glioma Theranostics.
    Norouzi M
    Pharmacol Res; 2020 Jun; 156():104753. PubMed ID: 32209363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy.
    Zhao YD; Muhetaerjiang M; An HW; Fang X; Zhao Y; Wang H
    Biomaterials; 2021 Jan; 268():120552. PubMed ID: 33307365
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.
    Siegler EL; Kim YJ; Chen X; Siriwon N; Mac J; Rohrs JA; Bryson PD; Wang P
    Mol Ther; 2017 Dec; 25(12):2607-2619. PubMed ID: 28919377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Tumor Microenvironment as a Barrier to Cancer Nanotherapy.
    Curtis LT; Frieboes HB
    Adv Exp Med Biol; 2016; 936():165-190. PubMed ID: 27739048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy.
    Lee ES; Shin JM; Son S; Ko H; Um W; Song SH; Lee JA; Park JH
    Adv Healthc Mater; 2019 Feb; 8(4):e1801320. PubMed ID: 30666822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The synergistic strategies for the immuno-oncotherapy with photothermal nanoagents.
    Zhang Y; Zhang G; Wang G; Wu L; Monteiro-Riviere NA; Li Y
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1717. PubMed ID: 33825343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy.
    Luo W; Zheng L; Zhang T
    Int Immunopharmacol; 2021 Jan; 90():107199. PubMed ID: 33246828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
    Rhodes KR; Green JJ
    Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms.
    Song W; Das M; Chen X
    Trends Cancer; 2020 Apr; 6(4):288-298. PubMed ID: 32209444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
    Sun B; Hyun H; Li LT; Wang AZ
    Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunomodulatory Nanomedicine.
    Bartneck M
    Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28383783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Application of nanotechnology in circumventing immunotolerance.
    Ma Y; Shen Y; Zhu B; Li D; Liu J
    Pharmazie; 2020 Oct; 75(10):470-477. PubMed ID: 33305719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
    Cadete A; Alonso MJ
    Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nanotechnology platforms for cancer immunotherapy.
    Yang Z; Ma Y; Zhao H; Yuan Y; Kim BYS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1590. PubMed ID: 31696664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combinatorial prospects of nano-targeted chemoimmunotherapy.
    Da Silva CG; Rueda F; Löwik CW; Ossendorp F; Cruz LJ
    Biomaterials; 2016 Mar; 83():308-20. PubMed ID: 26796043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.